Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 12Breast 5Gastrointestinal 3Genitourinary 2Thoracic 1Other solid neoplasm 1Head & Neck 1

Conditions

Advanced Solid Tumors 4Triple Negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Childhood Solid Tumors 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1Advanced Ovarian Cancer 1

Interventions

pembrolizumab 8fludarabine 4Cyclophosphamide 4amatuximab 3Thiotepa 3Nivolumab 3Ipilimumab 3Hyperthermic Intraperitoneal Chemotherapy 3Filgrastim 3Carboplatin 3budigalimab 2belinostat 2SS1(dsFv)PE38 2Platinum 2Peripheral Blood Stem Cell Transplantation 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2venetoclax 1talazoparib 1sodium thiosulfate 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1obinutuzumab 1naptumomab estafenatox 1fludarabine phosphate 1epacadostat 1durvalumab 1bosutinib 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × talazoparib × Other solid neoplasm × Clear all
NCT02567396 2017-04-24

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Withdrawn
BreastGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡